Does Cancer Treatment Accelerate Aging? скачать в хорошем качестве

Does Cancer Treatment Accelerate Aging?

New research reveals that Epigenetic Age Acceleration (EAA), not telomere length, predicts neurocognitive decline in childhood cancer survivors. We break down the data on premature biological aging. The Deep Dive In this episode of SciPulse, we analyze a cross-sectional study of 1,413 childhood cancer survivors to understand the long-term impact of treatment on biological aging. While Telomere Length (mLTL) has long been the standard for measuring cellular age, this new research published in Nature Communications suggests that Epigenetic Age Acceleration (EAA)—specifically measured by "clocks" like PCGrimAge and DunedinPACE—offers a far more accurate architecture for predicting cognitive impairment. We examine the methodology used to derive these epigenetic clocks and their correlation with specific neurocognitive deficits, including attention span, processing speed, and executive function. The analysis distinguishes between survivors treated with CNS-directed therapy versus non-CNS therapies, highlighting how specific biological mechanisms drive accelerated aging. Finally, we discuss the implications of these findings for future clinical interventions. If EAA serves as a reliable efficacy biomarker, it could revolutionize how we monitor long-term survivor health and screen for early-onset dementia risks. Academic Integrity Disclaimer: This analysis is for educational purposes only and presents a summary of peer-reviewed research. It is not medical advice. Please consult the original paper for the full data set and clinical context. 📄 Original Paper: https://www.nature.com/articles/s4146... #SciPulse #Epigenetics #CancerResearch #Neuroscience #BiologicalAging #Telomeres #ClinicalOncology #DunedinPACE #GrimAge #CognitiveScience #NatureCommunications #Biomarkers